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http:WHAT THIS PAPER ADDS
A reconﬁguration of TIA services reduced the median delay from symptom to CEA to 9 days. However, an audit
revealed that during the median 3-day period between transfer from the TIA clinic to undergoing CEA, 13% of
patients suffered recurrent events, despite having been previously started on aspirin. In the current audit, a
change to early implementation of dual antiplatelet therapy (in the TIA clinic after CT/MR exclusion of paren-
chymal haemorrhage) was associated with a ﬁvefold reduction in recurrent neurological events prior to expe-
dited CEA and a fourfold reduction in spontaneous embolization, compared with data observed in the preceding
audit. This was achieved without a signiﬁcant increase in major peri-operative bleeding complications.Objective: A daily Rapid-Access TIA Clinic was introduced in 2008, where symptomatic patients were started on
75 mg aspirin þ 40 mg simvastatin by the referring doctor, before attending the clinic. Following clinic
assessment, patients with 50e99% stenoses were transferred to the vascular unit for carotid endarterectomy
(CEA). In two audits (n ¼ 212 patients), the median delay from transfer to the vascular unit to undergoing CEA
was 3 days, during which time 28 patients (13%) suffered recurrent neurological events. It was hypothesized that
early introduction of dual antiplatelet therapy (by adding clopidogrel 75 mg once parenchymal haemorrhage was
excluded in the TIA clinic) might signiﬁcantly reduce recurrent events between transfer to the surgical unit and
undergoing CEA.
Methods: Prospective audit in 100 consecutive, recently symptomatic patients receiving dual antiplatelet
therapy. Endpoints were: prevalence of recurrent events between transfer from the TIA clinic and undergoing
CEA; rates of spontaneous embolization prior to undergoing CEA; and prevalence of haemorrhagic complications
Results: The median delay from symptom to CEA was 8 days (IQR 5e15). The median delay between transfer
from the TIA clinic to CEA was 3 days (IQR 2e5), during which time three patients (3%) suffered recurrent TIAs.
This represents a ﬁvefold reduction compared with previous audit data (OR 4.9, 95% CI 1.5e16.6, p ¼ .01) and
was matched by a fourfold reduction in the prevalence of spontaneous embolization from 39/189 (21%)
previously to 5/83 (5%) in the current audit (OR 4.1, 95% CI 1.5e10.7, p ¼ .0047). The 30-day death/stroke rate
was 1%. There were three haemorrhagic complications: stroke caused by haemorrhagic transformation of an
infarct; exploration for neck haematoma; and debridement and skin grafting for spontaneous shin haematoma.
Conclusion: Early introduction of dual antiplatelet therapy was associated with a signiﬁcant reduction in
recurrent neurological events and spontaneous embolization prior to CEA, without incurring a signiﬁcant increase
in major peri-operative bleeding complications.
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There has been an international move towards performing
carotid endarterectomy (CEA) as soon as possible after
onset of symptoms, driven by increasing awareness that the
highest risk period for recurrent stroke is the ﬁrst few days
after suffering a transient ischaemic attack (TIA) or minor
stroke.1e7
To deliver expedited CEA, a daily Rapid Access TIA service
was established in Leicester in October 2008.8 The referring
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a suspected TIA/minor stroke on 300 mg aspirin and 40 mg
simvastatin at the time of seeing the patient. A consultant
physician (who specialized in stroke medicine) then saw
each referral in the daily TIA clinic and was responsible for
optimizing risk factors and ensuring the patient was still
taking aspirin and a statin. Anyone with an ipsilateral 50e
99% ICA stenosis was transferred from the TIA clinic to the
vascular unit for urgent CEA.8
This protocol was associated with a reduction in the delay
from symptom to CEA to a median of 9 days (95% CI 7e
10).9 Following transfer from the TIA clinic, patients un-
derwent CEA within a median of 3 days. However, two
sequential audits showed that during this 3-day time period
(between transfer from the TIA clinic and undergoing CEA),
11% and 15% of patients (respectively) suffered recurrent
TIAs or strokes,9,10 emphasizing just how unstable under-
lying carotid plaques were during this early time period.
Following a review of practice, and with the aim of trying
to prevent recurrent symptoms between referral and sur-
gery, the stroke physicians and vascular surgeons proposed
adding 75 mg clopidogrel (i.e. implementing early dual
antiplatelet therapy) as soon as intracranial haemorrhage
(ICH) or parenchymal haemorrhage was excluded on CT/
MRI in the TIA clinic.
The principle aims of the current audit were to establish
whether earlier introduction of dual antiplatelet therapy
reduced the prevalence of recurrent events between
transfer from the TIA clinic and undergoing CEA, without
increasing the risk or peri-operative haemorrhagic
complications.MATERIALS AND METHODS
Between August 17, 2013 and July 27, 2014, 100 consecu-
tive, recently symptomatic patients undergoing CEA were
recruited. Asymptomatic patients undergoing CEA during
this time period were excluded. All patients had been
transferred to the vascular unit at the Leicester Royal In-
ﬁrmary via the Rapid Access TIA clinic, or acute stroke unit.
The Leicestershire, Northamptonshire and Rutland Research
ethics committee advised that this study did not fall under
the remit of the NHS research ethics committee, as it was
audit/service evaluation. This prospective audit was regis-
tered with the University Hospitals of Leicester Clinical
Audit and Quality Improvement Project (ref 6625).Rapid Access TIA clinic
October 2008eAugust 2013. The Rapid Access TIA clinic
started in October 2008 and operates every day of the
year.8 The referring family doctor/emergency department
doctor starts 300 mg aspirin and 40 mg simvastatin in
anyone suspected of having suffered a TIA/minor stroke.
Electronic referrals were triaged based on the patient’s
ABCD2 score.11 Patients with an ABCD2 score of 0e3 (7-day
predicted stroke risk ¼ 1%) were seen within 7 days of
referral. Patients with an ABCD2 score of 4e7 (7e10%predicted stroke risk within 7 days) were seen either the
same day or the following morning.
At the TIA clinic, baseline bloods were taken (haematol-
ogy/biochemistry) and patients underwent CT/MRI plus
carotid Duplex ultrasound assessment. A consultant stroke
physician then saw each patient and assumed responsibility
for optimizing risk factors and ensuring the patient was
taking aspirin and a statin. Any patient who had an ipsi-
lateral 50e99% carotid stenosis was transferred to the
vascular unit for urgent CEA. Following transfer, the aspirin
dose was reduced from 300 mg to 75 mg daily and this was
continued throughout the peri-operative period. Between
October 1, 2008 and August 16, 2013, it was unit policy for
all CEA patients to receive a single 75 mg dose of clopi-
dogrel the night before surgery (in addition to regular
aspirin therapy) to prevent early post-operative thrombo-
embolic stroke.12 However, no other doses of clopidogrel
were administered between admission and surgery during
this time period.
August 2013eJuly 2014: the current audit. The main pro-
tocol change related to the start date for dual antiplatelet
therapy. All other aspects of referral, investigation, and
treatment remained the same. Patients with an ipsilateral
50e99% stenosis and who had no evidence of ICH or
parenchymal haemorrhage on CT/MRI were started on
75 mg clopidogrel (in addition to their regular aspirin). Dual
antiplatelet therapy (75 mg aspirin, 75 mg clopidogrel) was
then continued throughout the peri-operative period.
Immediately prior to hospital discharge, aspirin was
stopped, but clopidogrel was continued as per NICE
guidelines.13 No patients in the current audit were taking
warfarin at the time of TIA clinic attendance.
Expedited CEA
The protocol for performing CEA did not change during the
6-year period from 2008 to 2014. Following admission, each
patient underwent work-up for theatre, the goal being to
perform CEA safely and as soon as possible. Poorly
controlled hypertension was relatively common and treat-
ment was started prior to surgery and then ‘ﬁnetuned’
following the procedure. Where necessary, referrals were
made to other medical disciplines for advice regarding the
treatment of comorbid conditions that might otherwise
delay surgery. Two half-day theatre lists were ‘ring-fenced’
for CEAs on Tuesdays and Fridays. If these lists were ﬁlled,
alternative arrangements were made (emergency theatre,
ad hoc space on elective lists, deferral to next unﬁlled CEA
list). During the current audit, CEA was performed only once
on a Saturday/Sunday.
CEA was performed in the same standardized manner
between 2008 and 2014, using general anaesthesia with
routine shunting/patching, intra-operative transcranial
Doppler (TCD) monitoring and completion angioscopy.12
The policy regarding the type of patch closure did, howev-
er, change. Between October 1, 2008 and December 31,
2011, ultrathin collagen-coated polyester patches were
used to close the arteriotomy (Hemagard Ultrathin, Atrium
414 A. Batchelder et al.Maquet Getinge Group) and each patient received a single
75 mg dose of clopidogrel the night before surgery in
addition to regular aspirin. Between January 1, 2012 and
August 16, 2013, a bovine pericardial patch was used to
close the arteriotomy (XenoSure Biologic Vascular Patch,
LeMaitre). Patients undergoing CEA during this time period
still received a single 75 mg dose of clopidogrel the night
before surgery in addition to regular aspirin. Between
August 17 and July 27, 2014 (the current audit period),
bovine pericardial patches were used to close the arterio-
tomy but every patient now started 75 mg clopidogrel once
ICH was excluded in the TIA clinic, in addition to regular
aspirin therapy.Table 1. Demographics, spontaneous embolization rates, median
delays to referral/treatment, and recurrent events prior to CEA.
Current audit Preceding audits p
n 100 212
Males:females 64:36 142:70 .610
Median age 74
(range 51e92)
72
(range 37e94)
.768
Past history
Treated
hypertension
76 (76%) 161 (76%) 1.00
Diabetes 33 (33%) 47 (22%) .052
Ischaemic heart
disease
21 (21%) 35 (17%) .346
Ex/current smoker 70 (70%) 157 (74%) .496
Presentation
TIA 66 (66%) 117 (55%) .085
Stroke 18 (18%) 64 (30%) .027
Amaurosis 16 (16%) 31 (15%) .737
Median delays
Index symptom
to CEA
8 days
(IQR 5e15)
9.5 days
(IQR 6e18)
.231
Referral to CEA 3 days
IQR 2e5)
3 days
(IQR 1e4)
.786Post-operative care
Patients were monitored for 3 hours in the recovery area of
theatre. Provided there was no haemodynamic instability or
neurological complications, patients were transferred back
to the vascular ward for ongoing care and were usually
discharged within 48 hours. Since 2008, the unit has
maintained an aggressive policy towards the management
of post-CEA hypertension. Written guidance on the man-
agement of post-CEA hypertension12 was placed in the case
notes of each patient so that treatment was never delayed.
Unit policy regarding the treatment of post-CEA hyperten-
sion policy did not change between October 2008 and July
2014.
Current audit. The current audit documented recurrent
neurological events in the time period between transfer
from the TIA clinic and undergoing CEA, along with 30-day
rates of death/stroke and any major peri-operative bleeding
complication (deﬁned as stroke caused by ICH, haemor-
rhagic transformation of a cerebral infarct, return to theatre
for evacuation of neck haematoma, gastro-intestinal blood
loss, and any spontaneous bleeding/haematoma that
otherwise delayed discharge). Two additional analyses were
undertaken to evaluate the effect of dual antiplatelet
therapy on reducing spontaneous embolization and peri-
operative haemorrhagic problems. Patients with an acces-
sible temporal window underwent a 30-minute period of
TCD monitoring on the afternoon prior to CEA to identify
patients with spontaneous embolization in the ipsilateral
middle cerebral artery.12 Similar data (regarding sponta-
neous embolization rates) were available from the two
preceding audits in 2010 and 2011.9,10
In addition, the time from ﬂow restoration to removal of
drapes was used as a surrogate for the delay to achieving
haemostasis. In view of the temporal changes in patch type
(and the effect/bias this might have had on haemostasis),
three consecutive patient cohorts were analyzed: (i) January
1, 2011 to December31, 2011: polyester patch with regular
aspirin þ 75 mg clopidogrel the night before surgery
(n ¼ 96); (ii) January 1, 2012 to May 31, 2013: bovine
pericardial patch with regular aspirin þ 75 mg clopidogrel
the night before surgery (n ¼ 122); and (iii) August 17, 2013
to July 27, 2014 (the current audit): bovine pericardial patchwith regular aspirin þ 75 mg clopidogrel starting once ICH
was excluded in the TIA clinic (n ¼ 100).
RESULTS
Between August 17, 2013 and July 27, 2014, 100 consecu-
tive patients with recent onset carotid territory symptoms
entered the audit. The cohort included 64 males and 36
females with a mean age of 74 years (range 51e92). Sixty-
six (66%) presented with a TIA, 18 (18%) with a stroke, and
16 (16%) with amaurosis fugax (Table 1). Seventy-six pa-
tients (76%) were on treatment for hypertension, 33 (33%)
were diabetic, 21 (21%) had a history of ischaemic heart
disease, while 70 (70%) were current/ex-smokers. Table 1
indicates how patient demographics in the current audit
compared with the 212 patients in the preceding audits.
With the exception of a signiﬁcantly higher prevalence of
stroke as a presentation in the preceding audits, there was
no systematic difference between the two patient cohorts.
The median ABCD2 score in the 100 patients in the current
audit was 5 (range 1e7). Thirty-ﬁve of the 100 patients
(35%) had CT/MRI evidence of recent acute infarction or
evolving ischaemic change.Delays to CEA
The median delay from presenting symptom to undergoing
CEA was 8 days (IQR 5e15), compared with a median of 9.5
days (IQR 6e18) in the 212 patients in the preceding audits
(p ¼ .231). The median delay from transfer from the TIA
clinic to undergoing CEA in the current audit was 3 days
(IQR 2e5 days), compared with a median of 3 days (IQR 1e
4) in the preceding audits (Table 1, p ¼ .786). Forty-four
patients (44%) in the current audit underwent surgery
within 48 hours of transfer from the TIA clinic, while 74
(74%) underwent surgery within 96 hours.
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Three patients in the current audit (3%) suffered recurrent
symptoms in the (median) 3-day period between transfer
from the TIA clinic and undergoing CEA. All were TIAs and
no-one suffered a recurrent stroke. Details regarding pre-
sentation, time of starting dual antiplatelet therapy, and
timing of recurrent symptoms are detailed in Table 2.
Interestingly, none of those patients suffering a recurrent
event had severe (70e99%) carotid stenoses; all had 50e
60% stenoses using the NASCET measuring method.
The 3% rate of recurrent events in the median 3-day
period between transfer from the TIA clinic to undergoing
CEA in the current audit represents a ﬁvefold reduction
compared with the 28/212 (13%) prevalence in the pre-
ceding audits (OR 4.9, 95% CI 1.5e16.6, p ¼ .01).Prevalence of embolization prior to CEA
Eighty-three of the 100 patients in the current audit had an
accessible transcranial window and underwent 30 minutesTable 2. Clinical details regarding the three patients who suffered
recurrent TIAs immediately prior to carotid surgery despite early
implementation of dual antiplatelet therapy.
Clinical details
Case 1 Hemispheric TIA at 16:45 on November 10
64-year-old
female
Seen in TIA clinic on morning of November 11
Carotid Duplex scan showed 50e60% stenosis of
ipsilateral ICA
Transferred to vascular unit at 15:00 h on
November 11
Clopidogrel administered at 17:50 h on
November 11
Recurrent hemispheric TIA November 12 (22 h
after clopidogrel started)
Case 2 Five hemispheric TIAs in preceding 4 days
86-year-old
male
Attended emergency department at 22:40 h on
December 22
Clopidogrel administered 23:45 h on December
22 (stroke physician advice)
Admitted to stroke unit at 00:44 h on December
23
Carotid Duplex scan 11:00 h on December 23: 50
e60% stenosis of ipsilateral ICA
Recurrent TIA on evening of December 23 (18 h
after clopidogrel started)
Case 3 Two hemispheric TIAs in preceding 7 days; seen
in peripheral hospital
70-year-old
male
Clopidogrel started on May 2 by referring stroke
unit
CT angiogram on May 3: 60% stenosis of
ipsilateral ICA
Recurrent hemispheric TIA 11:00 h on May 9
Transferred to vascular unit on afternoon of
May 9
Two hemispheric TIAs on evening of May10 (had
been taking clopidogrel for 8 days)of TCD monitoring on the afternoon prior to surgery. Five
(6%) had evidence of spontaneous embolization. In the
preceding audits, 189/212 (89%) had an accessible trans-
cranial window and underwent 30 minutes of TCD moni-
toring. In this group, 39/189 (21%) had evidence of
spontaneous embolization. Compared with the current
audit, this represents a fourfold reduction in the prevalence
of spontaneous embolization (OR 4.1, 95% CI 1.5e10.7,
p ¼ .0047).
Peri-operative bleeding complications
Three patients in the current audit (3%) suffered major
haemorrhagic complications within 30-days of surgery. One
suffered a stroke following haemorrhagic transformation of
a recent ischaemic infarction on day 2 after CEA. He had
presented with a non-disabling stroke (Rankin grade 2) 4
days prior to CEA. He underwent an uneventful procedure,
but suffered an acute worsening of his pre-existing neuro-
logical deﬁcit on the second post-operative day, in the
absence of post-CEA hypertension. He was transferred to
the stroke unit for rehabilitation and scored Rankin grade 2
at 30 days (non-disabling post-operative stroke). There were
no other strokes or deaths in the peri-operative period. The
second patient developed a neck haematoma that required
evacuation, while a third developed a spontaneous shin
haematoma that required debridement and skin grafting.
In the preceding audits involving 212 patients who did
not receive dual antiplatelet therapy (other than on the
night before surgery); no patient suffered an intracranial
haemorrhage but seven (3.3%) required re-exploration for
neck haematomas.
Time from restoration of ﬂow to removal of drapes
The time from ﬂow restoration to removal of drapes is a
surrogate marker for delays to achieving haemostasis. In
view of the temporal changes in patch type (and the effect/
bias this might have had on achieving haemostasis), three
consecutive patient cohorts were analyzed (Table 3). The
median delay from ﬂow restoration to drape removal in
patients whose arteriotomy was closed with a collagen-
coated, thin-walled polyester patch, and who were taking
regular aspirin and a single 75 mg dose of clopidogrel the
night before surgery (policy during all of the ﬁrst audit and 9
months of the second audit) was 31 minutes (IQR 26e41).
The change to using bovine pericardial patches, as was
practiced during the latter 4 months of the second audit,
(regular aspirin plus a single 75 mg dose of clopidogrel the
night before surgery), saw a signiﬁcant decrease in the
median time from ﬂow restoration to drape removal (26
minutes, IQR 21e32, p ¼ .021, Mann-Whitney U test). In
the current audit (where dual antiplatelet therapy was
started 3 days pre-operatively once parenchymal haemor-
rhage had been excluded on CT/MRA), all arteriotomies
were closed with bovine pericardial patches. Here, the
median delay from ﬂow restoration to drape removal
increased non-signiﬁcantly to 28 minutes (IQR 21e33,
p ¼ .5619, Mann-Whitney U test), compared with patients
Table 3. Median time from restoration of ﬂow to removal of surgical drapes in three cohorts of patients stratiﬁed for patch type and
antiplatelet strategy.
Assessment perioda Patch type Antiplatelet strategy n Median time (IQR)
01/01/11 to 31/12/11 Collagen-coated polyester 75 mg aspirin dailyb þ 75 mg clopidogrel night
before CEA
96 31 mins (26e41)
01/01/2012 to 31/05/2013 Bovine pericardial patch 75 mg aspirin dailyb þ 75 mg clopidogrel night
before CEA
122 28 mins (21e32)
Current audit
17/08/2013 to 27/07/2014
Bovine pericardial patch 75 mg aspirin dailyb þ 75 mg clopidogrel dailyc
starting in TIA clinic
100 28 mins (21e33)
a Because the type of carotid patch changed in the years prior to the current audit, the median delay from ﬂow restoration to drape
removal has been listed for two discrete time periods before the current audit was undertaken to see whether the introduction of dual
antiplatelet therapy was associated with a signiﬁcant prolongation in time to achieve haemostasis.
b Aspirin was started by the referring family or emergency room doctor once a TIA or minor stroke was suspected.
c Clopidogrel (dual antiplatelet therapy) was started once parenchymal haemorrhage was excluded on CT/MRI in the TIA clinic.
416 A. Batchelder et al.undergoing a bovine pericardial patched CEA and who only
received a single 75 mg dose of clopidogrel the night before
surgery in addition to their regular aspirin.
DISCUSSION
There has been a worldwide move towards performing CEA
as soon as possible after onset of symptoms. This has been
driven by awareness that the highest risk period for recur-
rent stroke in patients with ipsilateral 50e99% stenoses of
the internal carotid artery (ICA) is the ﬁrst few days after
onset of symptoms, with published prevalences ranging
from 5e8% at 48 hours,5e7 17% at 72 hours,3,7 8e22% at 7
days,2,3,5e7 and 11e25% at 14 days.2,5e7
The ability to perform CEA as soon as possible after onset
of symptoms cannot be achieved through ad hoc changes in
referral practices, no matter how enthusiastic some sur-
geons might be.14 The Leicester Rapid Access TIA service
was introduced in October 2008 through collaboration be-
tween vascular surgeons, stroke physicians, radiologists,
vascular technologists, hospital management, and health
purchasers.8 The net result was an immediate reduction in
delays to treatment for all TIA/minor stroke referrals but,
especially, CEA patients. Prior to 2008, the median delay
from referral to CEA in Leicester was 28 days,14 but this fell
immediately to 4 days after introduction of the daily TIA
clinic.8
One unanticipated consequence, however, of expediting
all aspects of the referral and admission process was that a
signiﬁcant proportion of patients suffered recurrent
neurological events in the (median) 3-day time period be-
tween transfer from the TIA clinic and undergoing CEA.
Historically, this was something that had not been
encountered previously, reﬂecting the greater delays be-
tween onset of symptoms and undergoing CEA that was
typical of most vascular units of the time.
Two sequential audits evaluated the prevalence of
recurrent symptoms between transfer from the TIA clinic
and undergoing CEA. In the 2011 audit, Salem reported that
18/123 patients (15%) suffered recurrent symptoms in the
(median) 3-day time period between transfer from the TIA
clinic and undergoing CEA.9 None, however, were strokes. In
a second (2013) audit, Ali observed that 10/89 patients
(11%) suffered recurrent neurological events (TIA ¼ 8;stroke ¼ 2) prior to surgery. Two strokes were disabling and
neither patient was ﬁt enough to undergo surgery.10 When
the two audits were combined, 28/212 patients (13%)
suffered recurrent neurological events in a median time
period of 3 days (IQR 1e4) between transfer from the TIA
clinic and undergoing surgery. Overall, the median delay
from index symptom to CEA for these 212 patients was 9.5
days (IQR 6e18), that is not signiﬁcantly different to the 8
days (IQR 5e15) observed in the current audit.
Similar experiences have been reported elsewhere,
although few have published data reporting recurrent
events so close to the index event. In Blaser’s series,15 the
median delay from index event to investigation was 19 days.
However, in the 10 days (median) between investigation
and undergoing CEA, 15 patients (10%) suffered recurrent
events (TIA ¼ 6; non-disabling stroke ¼ 1; disabling
stroke ¼ 8), while eight (6%) suffered an asymptomatic
occlusion of their ICA. In a similar series, but where patients
were seen at a median of 14 days after symptom onset,
Kastrup observed that during the next 7 days, 3% suffered a
recurrent TIA, while 12% developed new, asymptomatic
DWI lesions on MRI.16 Finally, Johannson observed that the
rate of recurrent ipsilateral stroke in patients with 50e99%
stenoses who were waiting for CEA was 5% at 48 hours
after the index event, 8% at 7 days, and 11% at 14 days.5 In
a recent Swedish study, Stromberg reported that 72% of
their cohort of patients who presented with a TIA/minor
stroke and a 50e99% stenosis were admitted on the day of
the referring neurological event.17 Thereafter, 2% suffered a
stroke within 48 hours of their presenting symptom,
increasing to 4% at 7 days. When ‘strokes in evolution’ were
included, 3.2% of patients had suffered a stroke within 48
hours.
The hypothesis underlying the current audit was that
earlier institution of dual antiplatelet therapy might reduce
the prevalence of recurrent events immediately prior to
CEA. This was based on the following clinical/scientiﬁc ob-
servations: (i) most recurrent events follow continuing
embolization from unstable carotid plaques; (ii) emboliza-
tion rates are highest in the very early time period after
onset of symptoms;9 (iii) the CARESS and CLAIR studies
showed that early institution of aspirin and clopidogrel
signiﬁcantly reduced rates of embolization in patients with
Dual antiplatelet therapy prior to CEA 417recent onset TIA/stroke;18,19 (iv) when aspirin and clopi-
dogrel were started <24 hours in patients suffering an
acute coronary syndrome, there was a signiﬁcant reduction
in cardiovascular death, non-fatal MI, and stroke;20 and (v) a
meta-analysis of four randomized trials showed that the
early introduction of aspirin and clopidogrel was associated
with a 34% relative risk reduction in stroke, TIA, acute
coronary syndrome, and all-cause death.21
In the current audit, only three patients (3%) suffered a
recurrent TIA during the median 3-day time period between
transfer from the TIA clinic and undergoing CEA. This rep-
resents a ﬁvefold reduction in the prevalence of recurrent
events, when compared with 28/212 patients (13%) in the
preceding audits when only aspirin monotherapy was
administered in the 3-day time period between transfer
from the TIA clinic and CEA9,10 (OR 4.9, 95% CI 1.5e16.6,
p ¼ .0102). This signiﬁcant reduction in recurrent events
was also associated with a fourfold reduction in the pro-
portion of patients with spontaneous embolization on pre-
operative TCD monitoring. It is, of course, accepted that this
is not a randomized comparison, but there were no signif-
icant differences in delays from index symptom to CEA and
from TIA clinic transfer to CEA in the preceding audits
(Table 1). Moreover, patient demographics were very
similar and there was no other difference in prescribing
practices. One confounding factor that was not considered
in this audit (nor in the preceding ones) was to document
the proportion of patients who were or were not already
taking antiplatelet agents prior to their symptoms starting.
This information was not recorded, but there is no reason to
believe that a systematic change in antiplatelet prescribing
had occurred between the three sequential audits.
Very few studies have speciﬁcally looked at the effect of
early implementation of dual antiplatelet therapy on pre-
venting recurrent events prior to CEA. Shahidi et al. re-
ported that 29% of their cohort of 115 recently
symptomatic patients awaiting CEA had suffered a recurrent
neurological event in the 90-day time period prior to the
neurological event that led to the patient’s referral for CEA.
Patients were then started on clopidogrel (in addition to
regular aspirin), prior to surgery. During a median 6-day
period between referral and CEA, only 2.5% suffered
recurrent events.22 Accordingly, the current audit (as well as
Shahidi’s data) suggest that the early introduction of dual
antiplatelet therapy is associated with a signiﬁcant reduc-
tion in the prevalence of recurrent neurological events
during this (previously) high-risk period, presumably caused
by a signiﬁcant reduction in spontaneous embolization. It
might, however, be speculated that the median 3-day time
period between transfer from the TIA clinic to undergoing
CEA was too short a time period for dual antiplatelet
therapy to exert a meaningful effect. However, a prospec-
tive, randomized trial has previously shown that a single
75 mg dose of clopidogrel given the night before surgery
reduced platelet aggregation to ADP by 40% by the
following day, suggesting that 3 days of dual antiplatelet
therapy should be capable of exerting a clinically signiﬁcant
antiplatelet effect.Notwithstanding the clinically important beneﬁt (to the
patient) of reducing recurrent events prior to surgery, sur-
geons remain concerned that dual antiplatelet therapy will
be associated with a signiﬁcant increase in major bleeding
complications during the peri-operative period. However,
only three patients (3%) in the current audit suffered major
haemorrhagic complications and this does not represent a
signiﬁcantly increased level of risk compared with historical
controls in the literature or when compared with the 212
patients in the two preceding audits. The prevalence of re-
exploration for neck haematoma (1% in the current audit)
was no different to that reported in other contemporary
audits. In a series of 5264 CEAs from the Vascular Study
Group of New England, the prevalence of re-exploration for
neck haematoma was 1.5% in patients not taking any an-
tiplatelet therapy, 1.2% in patients taking aspirin, 0.7% in
patients taking clopidogrel, and 1.4% in patients taking
aspirin and clopidogrel.23 Other single centre studies have
also reported that performing CEA in patients on dual an-
tiplatelet therapy is not associated with an increase in re-
exploration for neck haematomas,24 while the Interna-
tional Carotid Stenting Study reported a prevalence of 3.4%
for neck haematomas requiring re-exploration following 821
CEAs.25 It is, however, conceded that the spontaneous shin
haematoma was probably a direct consequence of dual
antiplatelet therapy, but this was the only example of
spontaneous peripheral bleeding in this series and there
were no cases of acute gastrointestinal haemorrhage.
One patient (1%) did, however, suffer haemorrhagic
transformation in an area of recent cerebral infarction. This
was the only stroke that occurred in the peri-operative
period in the current audit. Interestingly, this happened
without any associated increase in blood pressure. It is
possible, however, that had such an aggressive policy not
been adopted towards the treatment of post-CEA hyper-
tension,12 untreated surges in blood pressure (in the pres-
ence of dual antiplatelet therapy) might have predisposed
towards a much higher prevalence of ICH and haemorrhagic
infarct transformation. This is probably an important addi-
tional message to come from this audit.
Finally, the choice of patch may be an important factor
following the introduction of dual antiplatelet therapy prior
to CEA. The Leicester unit changed from a collagen-coated,
polyester patch to a bovine pericardial patch following
publication of a systematic review of prosthetic patch in-
fections, which showed that early patch infection (within 3
months of surgery) was associated with early wound com-
plications including wound haematoma. It has previously
been shown that the addition of a single 75 mg dose of
clopidogrel (to regular aspirin) the night before surgery
adds an average of 20 minutes to the time from ﬂow
restoration to removal of drapes, reﬂecting an increase in
the time to achieve haemostasis.26 It was hypothesized that
changing from a prosthetic to a biological patch would
achieve more rapid haemostasis (and hence fewer wound
haematomas) and this was borne out in this audit where
the median delay from ﬂow restoration to drape removal
decreased by 5 minutes from 31 minutes (polyester
418 A. Batchelder et al.patch þ75 mg clopidogrel the night before surgery) to 26
minutes (bovine pericardial patch þ 75 mg clopidogrel the
night before surgery). More importantly, starting dual an-
tiplatelet therapy 3 days prior to CEA was only associated
with a (non-signiﬁcant) 2-minute increase in the median
time from ﬂow restoration to drape removal, compared
with bovine pericardial-patched patients receiving a single
dose of clopidogrel the night before surgery (Table 3).
In conclusion, the early introduction of dual antiplatelet
therapy was associated with a ﬁvefold reduction in recur-
rent neurological events prior to expedited CEA and a
fourfold reduction in spontaneous embolization, when
compared with historical controls. This was achieved
without a signiﬁcant increase in major peri-operative
bleeding complications or delays to secure haemostasis,
although it is accepted that the risk of haemorrhagic stroke
might have been considerably higher had the unit not
adopted such an aggressive policy towards the treatment of
post-CEA hypertension. Given these ﬁndings, one might
now reasonably speculate that because the vast majority of
TIA/AFx patients are unlikely to have underlying paren-
chymal haemorrhage at the time of presentation, it may be
reasonable for the family doctor or emergency room doctor
to commence dual antiplatelet therapy as soon as possible
in any patient whose symptoms resolve within 24 hours,
rather than simply start aspirin and await a CT/MRI scan in
the TIA clinic before converting to dual antiplatelet therapy.
In that way, it may prove possible to further reduce the risk
of recurrent events in the 5e7 days that it takes patients to
seek medical advice and be referred to specialist clinics.
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Acute Monocular Blindness after Carotid Endarterectomy due to
Non-arteritic Anterior Ischemic Optic Neuropathy
P. Konstantiniuk *, T. Cohnert
Medical University of Graz, AustriaA 56 year old non-diabetic male patient with an asymptomatic 90% stenosis of the right internal carotid artery underwent
carotid endarterectomy with patch angioplasty. Thirty hours after surgery the patient’s right eye was sore and light
perception completely vanished without recovery. Nuclear magnetic resonance spectroscopy revealed a new occlusion of
the external carotid artery (right). Five days after surgery optic disc edema developed so NAION (non-arteritic anterior
ischemic optic neuropathy) was diagnosed (left). This entity has to be distinguished from posterior ischemic optic neu-
ropathy without ophthalmoscopic changes and from central retinal artery occlusion with a “cherry red spot” and sur-
rounding pale retina.
